People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Biotechnology, Pharmaceuticals, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Viracta Therapeutics, INC. | — | Biotechnology | Series C | $164.6M | $2.1B | 2010 |
| Syndax Pharmaceuticals Inc | — | Pharmaceuticals | Series C | $139.5M | $2.1B | 2014 |
| LigoCyte Pharmaceuticals Inc | — | Pharmaceuticals | Series B | $50.1M | $68.0M | 2010 |
| Biocept Inc | — | Biotechnology | Series A | $35.7M | $366.4M | 2011 |
| Altair Therapeutics, Inc. | — | Biotechnology | Series A | $6.5M | $233.8M | 2009 |
| Targegen Inc | — | Biotechnology | Seed | $3.7M | $165.6M | 2009 |
| Lions Mate With Lions, Ltd Liability Co | — | Other | Pre-Seed | $175K | $460K | 2025 |
Ivor Royston at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ivor Royston on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ivor Royston, M.D. | 2 | 2 |
| Todd Johnson | 1 | 27 |
| Patrick Soon-Shiong | 1 | 16 |
| David F Hale | 1 | 16 |
| Ben Auspitz | 1 | 9 |
| Jason Brown | 1 | 7 |
| Dennis Podlesak | 1 | 6 |
| Kim Kamdar | 1 | 6 |
| Pratik Shah | 1 | 5 |
| Joel Martin | 1 | 5 |
| Arlene Morris | 1 | 5 |
| David Shapiro | 1 | 4 |
| Hironori Hozoji | 1 | 4 |
| C. Boyd Clarke | 1 | 4 |
| Annette Bianchi | 1 | 4 |
| Roger Pomerantz | 1 | 4 |
| James Woody | 1 | 4 |
| Paul Goddard | 1 | 4 |
| David Hale | 1 | 4 |
| Barry Simon | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.